Physician profile
John Brainard
NPI 1104211085
$1,336.26
in general payments reported to CMS, 2019-2025
24 companies · $126 in 2025
The $126 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $257 · 2020: $97.00 · 2021: $191 · 2022: $193 · 2023: $332 · 2024: $141 · 2025: $126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $599.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $598.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $194.80 | 2022-2024 | Azstarys |
| Cranial Technologies, INC | $181.31 | 2019-2024 | Doc Band |
| Glaxosmithkline, LLC. | $179.06 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Sobi, INC | $128.60 | 2019-2023 | |
| Supernus Pharmaceuticals, INC. | $102.16 | 2021-2025 | Qelbree, Qelbree |
| Kaleo, INC. | $80.43 | 2022-2024 | Auvi-Q |
| Tris Pharma INC | $53.38 | 2019-2021 | |
| Sanofi Pasteur INC. | $47.62 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $39.88 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.08 | 2023-2024 | Flumist Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $30.54 | 2021 | |
| Merck Sharp & Dohme LLC | $27.75 | 2020-2021 | |
| Genentech USA, INC. | $25.20 | 2019-2020 | |
| Adlon Therapeutics L.P. | $24.60 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $23.81 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $22.33 | 2023 | Spinraza |
| Mylan Pharmaceuticals INC. | $21.95 | 2019 | |
| Noven Therapeutics, LLC | $17.73 | 2024 | Xelstrym |
| Collegium Pharmaceutical, INC. | $17.03 | 2025 | Jornay Pm |
| Azurity Pharmaceuticals, INC. | $17.03 | 2025 | Alvesco |
| Neurelis, INC. | $16.51 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.98 | 2024 | Zoryve |
| Shire North American Group INC | $15.98 | 2019 | |
| Pfizer INC. | $15.50 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brainard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.